A Phase 3 interventional study of insulin degludec/liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 87 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-27.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 28th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 28th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 435 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 120th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 309th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled with SU (sulphonylurea) alone or in combination with metformin. All subjects will continue their pre-trial SU treatment with or without metformin treatment without changing the frequency or dose throughout the trial.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 435 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: placebo
Drug pages: Insulin degludec · Liraglutide
Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Injected subcutaneously (under the skin) once daily.
Change in Glycosylated Haemoglobin (HbA1c)
Change in HbA1c from baseline to 26 weeks.
Time frame: Week 0, Week 26
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)
Percentage of subjects having HbA1c below 7% at week 26.
Time frame: Week 26
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)
Percentage of subjects having HbA1c below 6.5% at week 26
Time frame: Week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in FPG at week 26.
Time frame: Week 0, week 26
Change From Baseline in Body Weight
Change from baseline in body weight at week 26.
Time frame: Week 0, week 26
Number of Treatment Emergent (Confirmed) Hypoglycaemic Episodes
An event was treatment emergent if the onset of the episode occurs after the first administration of trial product and no later than 7 days after last trial product administration. Confirmed hypoglycaemic episodes were defined as hypoglycaemic episodes that were either severe or minor. Minor hypoglycaemic episodes were defined as: 1. An episode with symptoms consistent with hypoglycaemia and confirmed by blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) and which was handled by the subject himself/herself. 2. Any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or blood glucose value \<2.8 mmol/L (50 mg/dL). Severe hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Reported values are hypoglycemia event rate per 100 patient-years of exposure (PYE).
Time frame: After 26 weeks of treatment
Number of Adverse Events (AEs)
An AE was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. Reported values are hypoglycemia event rate per 100 PYE.
Time frame: After 26 weeks of treatment
The trial was conducted at 77 sites in 7 countries: Bulgaria (7), Canada (9), Germany (6), India (6), Israel (7), Turkey (3), United States (39).
| Milestone | IDegLira | Placebo |
|---|---|---|
| Started | 289 | 146 |
| Exposed | 288 | 146 |
| Completed | 251 | 111 |
| Not completed | 38 | 35 |
| Withdrew: Protocol violation | 13 | 10 |
| Withdrew: Adverse event | 9 | 2 |
| Withdrew: Withdrawal criteria | 2 | 10 |
| Withdrew: Unclassified | 14 | 13 |
Change in HbA1c from baseline to 26 weeks.
| percentage of glycosylated haemoglobin | IDegLira | Placebo |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -1.45 ± 0.84 | -0.46 ± 0.83 |
Percentage of subjects having HbA1c below 7% at week 26.
| percentage of subjects | IDegLira | Placebo |
|---|---|---|
| Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol) | 79.2 | 28.8 |
Percentage of subjects having HbA1c below 6.5% at week 26
| percentage of subjects | IDegLira | Placebo |
|---|---|---|
| Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol) | 64 | 12.3 |
Change from baseline in FPG at week 26.
| mmol/L | IDegLira | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -2.6 ± 2.61 | -0.31 ± 2.43 |
Change from baseline in body weight at week 26.
| kilogram | IDegLira | Placebo |
|---|---|---|
| Change From Baseline in Body Weight | 0.5 ± 3.1 | -1 ± 2.6 |
An event was treatment emergent if the onset of the episode occurs after the first administration of trial product and no later than 7 days after last trial product administration. Confirmed hypoglycaemic episodes were defined as hypoglycaemic episodes that were either severe or minor. Minor hypoglycaemic episodes were defined as: 1. An episode with symptoms consistent with hypoglycaemia and confirmed by blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL) and which was handled by the subject himself/herself. 2. Any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or blood glucose value \<2.8 mmol/L (50 mg/dL). Severe hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Reported values are hypoglycemia event rate per 100 patient-years of exposure (PYE).
| event rate per 100 PYE | IDegLira | Placebo |
|---|---|---|
| Number of Treatment Emergent (Confirmed) Hypoglycaemic Episodes | 351.7 | 135.2 |
An AE was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. Reported values are hypoglycemia event rate per 100 PYE.
| event rate per 100 PYE | IDegLira | Placebo |
|---|---|---|
| Number of Adverse Events (AEs) | 401.4 | 367 |
Collected over After 26 weeks of treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegLira | — | 14/288 (4.9%) | 83/288 (28.8%) |
| Placebo | — | 5/146 (3.4%) | 38/146 (26%) |
| Event | IDegLira | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 2/288 | 0/146 |
| Atrioventricular block second degreeCardiac disorders | 0/288 | 1/146 |
| BronchitisInfections and infestations | 0/288 | 1/146 |
| Dengue feverInfections and infestations | 0/288 | 1/146 |
| Impaired gastric emptyingGastrointestinal disorders | 0/288 | 1/146 |
| Stab woundInjury, poisoning and procedural complications | 0/288 | 1/146 |
| Acute myocardial infarctionCardiac disorders | 1/288 | 0/146 |
| Amylase increasedInvestigations | 1/288 | 0/146 |
| Anal abscessInfections and infestations | 1/288 | 0/146 |
| ArrhythmiaCardiac disorders | 1/288 | 0/146 |
| Event | IDegLira | Placebo |
|---|---|---|
| Lipase increasedInvestigations | 27/288 | 6/146 |
| NasopharyngitisInfections and infestations | 25/288 | 12/146 |
| DyslipidaemiaMetabolism and nutrition disorders | 19/288 | 6/146 |
| HeadacheNervous system disorders | 15/288 | 8/146 |
| InfluenzaInfections and infestations | 8/288 | 8/146 |
Full analysis set (FAS) included all randomized subjects.
| Age, Continuous(years) | IDegLira | Placebo | Total |
|---|---|---|---|
| Mean | 60 ± 9.6 | 59.4 ± 10.8 | 59.8 ± 10.0 |
| Sex: Female, Male(Participants) | IDegLira | Placebo | Total |
|---|---|---|---|
| Female | 135 | 73 | 208 |
| Male | 154 | 73 | 227 |
| Glycosylated haemoglobin(percentage of glycosylated haemoglobin) | IDegLira | Placebo | Total |
|---|---|---|---|
| Mean | 7.9 ± 0.6 | 7.9 ± 0.6 | 7.9 ± 0.6 |
| Fasting plasma glucose(mmol/L) | IDegLira | Placebo | Total |
|---|---|---|---|
| Mean | 9.1 ± 2.2 | 9.1 ± 2.1 | 9.1 ± 2.1 |
| Body weight(kilograms) | IDegLira | Placebo | Total |
|---|---|---|---|
| Mean | 87.2 ± 18.6 | 89.3 ± 17.5 | 87.9 ± 18.2 |
Ran from Aug 2012 to primary completion in Oct 2013, 13 months.
Results were first posted in Feb 2017, 3 years 3 months after primary completion. A results delay was requested in Nov 2013.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide